ADEPT® Adhesion Reduction Solution [4% Icodextrin]
ADEPT®Adhesion Reduction Solution is indicated for use intraperitoneally as an adjunct to good surgical technique for the reduction of post-surgical adhesions in patients undergoing gynecological laparoscopic adhesiolysis.
Important ADEPT® Safety InformationFor more information, please refer to the ADEPT® Adhesion Reduction Solution [4% icodextrin] Instructions for Use.
ADEPT® is the first FDA-cleared device for adhesion reduction in gynecologic laparoscopic surgery. The pivotal study was the first double-blind, randomized controlled clinical trial in adhesion reduction.2
ADEPT® has been studied in the USA in two pilot studies and one double-blind pivotal study in female patients undergoing gynecological laparoscopic surgery with a planned second look laparoscopy.
In the sub-group of patients presenting with a primary diagnosis of infertility, significantly more infertility patients (52.9%) had a reduction in AFS score compared with the LRS group (30.4%) p=0.001. Not adjusted for multiplicity.1
1st Look Laparoscopy, Pre-Adhesiolysis of Right Tubo-Ovarian Adhesions
2nd Look Laparoscopy, Status Post Right Tubo-Ovarian Adhesiolysis
1st Look Laparoscopy, Pre-Adhesiolysis of Left Adnexal Adhesions
2nd Look Laparoscopy, Status Post Adhesiolysis of Left Adnexal Adhesions
1st Look Laparoscopy, Pre-Adhesiolysis of Right Ovarian Fossa Adhesions
2nd Look Laparoscopy, Status Post Adhesiolysis of Right Ovarian Fossa Adhesions
Significantly more patients in the ADEPT® group, 49% versus the LRS group, 38% (P=.018) were classified as a clinical success* in the per protocol population (n=402).2
*Clinical success was defined as a reduction in adhesions of at least 3 or 30% of sites lysed (whichever was greater) between the initial surgery and the follow-up laparoscopy.2